IDC MarketScape Positions Accenture a Leader in Life Science Sales and Marketing IT Outsourcing Services
NEW YORK; April 28, 2022 – Accenture (NYSE: ACN) is positioned as a leader in the IDC MarketScape analysis of life science sales and marketing IT outsourcing services in 2022.
April 28, 2022
Accenture Joins AI4BetterHearts Data Collaborative
NEW YORK; March 29, 2022 – Accenture (NYSE: ACN) has joined AI4BetterHearts, a global data collaborative founded by Microsoft and the Novartis Foundation, that aims to help stakeholders —
from policy makers to patients — make better decisions about heart health and improve the health of entire populations.
from policy makers to patients — make better decisions about heart health and improve the health of entire populations.
March 29, 2022
Nine Out of Ten Healthcare Executives Say That Health Equity Initiatives are a Top Business Priority, According to Accenture and HIMSS Insights
NEW YORK; March 15, 2022 – New research from Accenture (NYSE: ACN) and HIMSS Market Insights reveals that 93% of U.S. healthcare executives believe that health equity initiatives are important and 89% agree that such initiatives are part of their core business strategy. However, only slightly more than a third (36%) have a specific budget dedicated to advancing their health equity agendas.
March 15, 2022
Accenture and Microsoft to Assist Mt. Sinai Health System on Five-Year Transformation Journey to Cloud
NEW YORK; March 1, 2022 – Accenture (NYSE: ACN) and Microsoft (NYSE: MSFT) will assist the Mount Sinai Health System (Mount Sinai) with its transition to the cloud to help enable innovation at a much faster pace. By modernizing its infrastructure, Mount Sinai will be able to reinvest cost-savings and focus on its healthcare mission.
March 01, 2022
Accenture Helping Astellas Pharma Create Next-Generation Cloud-Based IT Core Platform for Advanced Real-Time Decision Making
TOKYO; Feb. 24, 2022 – Accenture (NYSE: ACN) helped Astellas Pharma Inc. create a cloud-based core IT platform that serves as the foundation for an advanced, data-driven management model for the company’s global operations. The new platform has been rolled out in Japan, the Americas and EMEA, with plans for further deployments.
February 24, 2022
Accenture and Organon Team Up to Drive Digital Transformation for Better Patient and Employee Experiences
NEW YORK; Nov. 17, 2021 – Accenture (NYSE: ACN) has been selected by Organon (NYSE: OGN), a global health care company, to help establish and manage the transformation of the company’s enterprise resource planning (ERP) technology into a cloud-based digital core that will improve patient and employee experiences.
November 17, 2021
Accenture Invests in Geneyx to Expand the Use of Genetic Data for Targeted and Personalized Therapeutics and Diagnostics
NEW YORK; Nov. 9, 2021 – Accenture (NYSE: ACN) has made a strategic investment, through Accenture Ventures, in Geneyx Genomex Ltd. (Geneyx), an Israel-based developer of genomic analysis and interpretation software. Geneyx helps improve patient outcomes associated with hereditary and rare diseases by providing disease-specific, clinically relevant insights around risk prediction, diagnosis, prognosis, and treatment for clinical and pharmaceutical organizations.
November 09, 2021
Accenture Positioned as a Leader in IDC MarketScape: Worldwide Life Sciences Research & Development Vendor Assessment on IT Outsourcing for Fourth Consecutive Report
NEW YORK; Nov. 1, 2021 – For the fourth consecutive time, Accenture (NYSE: ACN) is positioned as a Leader in the IDC MarketScape vendor assessment covering IT outsourcing (ITO) across the life sciences research and development (R&D) industry.
November 01, 2021
Biopharma Can Reduce the Cost of Bringing A Treatment to Market by More Than US$1 Billion, According to Accenture Report
NEW YORK; Oct. 26, 2021 – A new report from Accenture (NYSE: ACN) identifies three steps biopharmaceutical organizations could take to reduce the average cost of discovering and developing a treatment by more than US$1 billion. Furthermore, it could potentially create additional future revenue opportunities of up to US$450 million per treatment.
October 26, 2021
Accenture Named a Leader in the IDC MarketScape: Worldwide Life Science R&D BPO Services 2021 Vendor Assessment
NEW YORK; Sept. 30, 2021 – Accenture (NYSE: ACN) has been named a Leader in life science research and development (R&D) and business process outsourcing (BPO) services capabilities, according to a new a worldwide IDC MarketScape assessment.
September 30, 2021